Invion

Invion Receivables

The Accounts Receivable of Invion (IVX.AX) as of Oct 18, 2026 is 140,000.00 AUD. In the previous year, Accounts Receivable was 11,000.00 AUD — a change of 1,172.73% (higher).

Receivables

140,000.00AUD

YoY

1,172.73%

Last updated:

Accounts Receivable of Invion is 2022 140,000.00 AUD. Accounts Receivable of Invion was 2021 11,000.00 AUD. It decreases by 1,172.73% higher compared to the previous year.

The Invion Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2016
647,500.00 AUD
Jan 1, 2017
32,300.00 AUD
Jan 1, 2018
91,800.00 AUD
Jan 1, 2019
28,800.00 AUD
Jan 1, 2020
247,300.00 AUD
Jan 1, 2021
11,000.00 AUD
Jan 1, 2022
140,000.00 AUD
The Invion Receivables history
YEARReceivablesYoY
140,000.00AUD+1,172.73%
11,000.00AUD-95.55%
247,300.00AUD+758.68%
28,800.00AUD-68.63%
91,800.00AUD+184.21%
32,300.00AUD-95.01%
647,500.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Accounts Receivable of Invion is 140,000.00 AUD in 2022.

Accounts Receivable of Invion changed from 11,000.00 AUD to 140,000.00 AUD, representing a 1,172.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Invion since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Invion

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Invion